Understand how testosterone, LH and related tests help assess the male hormone control system, with context on repeat testing, symptoms and fertility.
The male hormone control system is the communication between the hypothalamus and pituitary in the brain and the testes that helps regulate testosterone production. Clinicians assess this system by looking at testosterone alongside pituitary hormones such as LH and FSH. The relationship between these results helps distinguish impaired testicular function from inadequate signals to the testes.
This article is for informational purposes only and is not medical advice. A qualified clinician should interpret personal results and make diagnosis or treatment decisions.
The EAU guideline on male hypogonadism makes an important distinction: testosterone production may be affected by a problem in the testes or by inadequate stimulation from the hypothalamic-pituitary system. These are different clinical patterns even when both involve low testosterone.
A testosterone measurement describes the hormone concentration in the blood sample. LH and FSH add information about the signalling associated with testicular function. Reading them together gives the clinician more context than treating each result as a separate pass-or-fail test.
The key numerical threshold in this guideline is 12 nmol/L for total testosterone. The EAU recommends repeating measurements below this value before starting testosterone therapy. This is a clinical decision threshold rather than a complete reference interval or an automatic indication for treatment.
The distinction matters biologically. A low testosterone concentration does not explain whether the testes are functioning poorly or receiving inadequate stimulation. The accompanying pituitary hormone results help address that question.
The guideline recommends morning sampling between 07:00 and 10:00, using a reliable assay and fasting conditions. For late-onset hypogonadism, diagnosis combines compatible symptoms with low morning total testosterone on at least two occasions.
The practical point is to separate a measurement from a confirmed clinical pattern. One sample records a concentration under particular conditions. Repeat testing helps establish whether a low result persists under the conditions recommended for assessment.
Our explanation of why confirmation involves another blood draw provides further context for that process.
The EAU describes impaired testicular function as primary hypogonadism, also called hypergonadotropic hypogonadism. In this pattern, low testosterone occurs alongside increased gonadotropins.
Low testosterone with elevated LH is therefore consistent with a testicular-level problem. The useful information is the relationship between the low testosterone result and the higher pituitary signal. It helps locate a possible problem without establishing its precise cause.
The guideline describes inadequate hypothalamic-pituitary stimulation as secondary hypogonadism, also called hypogonadotropic hypogonadism. Here, gonadotropins are low or inappropriately normal alongside low testosterone.
“Inappropriately normal” means that a result needs to be judged against its hormonal context. An LH result within its laboratory interval may still be clinically relevant when testosterone is low. The printed reference flag is not the whole interpretation.
These patterns help explain why companion hormone measurements matter. They support an assessment of where the problem may originate rather than identifying a specific cause by themselves.
The EAU also describes a compensated or subclinical pattern: normal testosterone with elevated LH. It states that the clinical significance of this pattern is unclear.
That finding should therefore prompt discussion about its meaning in the individual case rather than an assumption that a disease or treatment need has been established. Normal testosterone with high LH is not the same pattern as low testosterone with high LH.
When total testosterone is pathologically low, the EAU recommends measuring LH together with prolactin to help identify the underlying condition. It also says that LH and FSH can support differentiation between hypogonadism types.
These tests answer related questions but are not interchangeable. A useful clinical explanation should connect each requested test to the concern being assessed. The aim is a coherent interpretation of the results rather than simply a longer list of measurements.
For adult men being assessed for possible testosterone deficiency, symptoms are part of the clinical picture rather than a direct measurement of hormone signalling. The EAU cautions that symptoms associated with hypogonadism are not specific to that condition.
This means that symptoms require attention without proving their hormonal cause. The clinical assessment brings them together with repeated testosterone measurements and other relevant findings. A symptom description alone does not establish whether the testes or their central stimulation are responsible.
For an appointment, it is useful to describe the concern separately from the suspected explanation. What has changed is one question. Whether testosterone is consistently low is another. How the related hormone results fit together is a further question.
Keeping those questions separate supports a more focused discussion. It allows a clinician to assess the symptoms while also checking whether the biochemical findings meet the guideline’s diagnostic framework.
The EAU recommends considering other medical conditions alongside medicines and substances that may interfere with the hypothalamic-pituitary-testicular system. It also identifies factors that affect SHBG and therefore the interpretation of total testosterone.
These influences should not all be treated as equivalent. Some affect the hormonal system itself. Others change the context in which a testosterone result is interpreted.
Acute illness can cause functional hypogonadism. The EAU therefore advises avoiding testosterone measurement during acute illness.
The timing of a blood sample is consequently more than an administrative detail. A clinician needs to know whether an illness was present when the sample was taken. That context belongs alongside the result when considering whether further assessment is needed.
The guideline lists obesity and insulin resistance among factors associated with lower SHBG. Ageing is associated with higher SHBG. Some conditions and medicines can also alter SHBG.
Because total testosterone can change with SHBG levels, the EAU recommends measuring SHBG and calculating free testosterone when altered SHBG is suspected. This adds context to the total testosterone result rather than replacing the wider clinical assessment.
The distinction is useful when discussing total and free testosterone measurements. A question about an unexpectedly low total result may also be a question about SHBG and the relevance of calculated free testosterone.
The EAU identifies medicines and substances as possible influences on the hormonal system. Some medicines are also associated with changes in SHBG.
A medication and substance history therefore belongs in the interpretation of hormone testing. The relevant discussion is whether an exposure could help explain the findings or affect their meaning. Personal decisions about changing prescribed treatment remain with the treating clinician.
Exogenous testosterone means testosterone supplied from outside the body. The EAU notes that it suppresses pituitary gonadotropin secretion and can impair sperm production.
This makes fertility goals relevant to the discussion of low testosterone. Supplying testosterone and supporting sperm production are not automatically the same treatment objective.
The guideline describes gonadotropin treatment as potentially maintaining testosterone and restoring sperm production in men with secondary hypogonadism who desire paternity. That is a specialist treatment consideration rather than a self-directed alternative. The underlying hormonal pattern and the person’s fertility goals both matter to qualified care.
“Was my low testosterone confirmed on a separate fasting morning sample; how do LH and FSH fit the result; are prolactin and SHBG relevant; could illness or medicines affect interpretation; and how would fertility goals change the discussion?”
Unexplained symptoms can make a hormone-control pathway seem more conclusive than it is. Testostra connects its coverage of low testosterone symptoms with readable explanations of testing and biomarkers, helping men prepare better-informed questions about possible causes without presenting education as a personal diagnosis.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.
Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra